Literature DB >> 26183456

Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma.

Mixue Xie1, Weihao Zhai2, Shiyu Cheng1, Hongdi Zhang1, Yanhui Xie1, Wei He2.   

Abstract

OBJECTIVES: To evaluate the predictive significance of F-18 FDG PET/CT quantization parameters for progression-free survival (PFS) in patients with diffuse large B cell lymphoma (DLBCL) before chemotherapy.
METHODS: We conducted a retrospective study involving 60 patients with DLBCL between January 2010 and August 2014 who had undergone F-18 FDG PET/CT scan prior to treatment. Maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and number of enlarged lymph nodes (>2 cm) were measured. The primary outcome measure was PFS. Spearman rank correlation analysis, univariate and multivariate Cox regression models, receiver operating characteristic (ROC) analysis, and Kaplan-Meir survival curves were used.
RESULTS: Spearman analysis determined that the MTV and TLG values were positively related to Ann Arbor stage, National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) score, and lactate dehydrogenase (LDH) level. The number of enlarged lymph nodes was positively related only to LDH level. The SUVmax value and clinical characteristics were not related. Univariate Cox regression determined that the MTV and TLG values, number of enlarged lymph nodes, and NCCN-IPI score were predictive factors. Multivariate Cox regression determined that the MTV and TLG values and number of enlarged lymph nodes predicted PFS independently of the NCCN-IPI score. The SUVmax value was not predictive of PFS. According to the cut-off determined from ROC analysis, lower MTV and TLG values were highly predictive of favorable PFS.
CONCLUSIONS: In contrast to SUVmax, the MTV and TLG may be significant prognostic markers for PFS in DLBCL.

Entities:  

Keywords:  Diffuse large B-cell lymphoma; PET/CT; Predictor; Progression-free survival; Quantization parameter

Mesh:

Substances:

Year:  2015        PMID: 26183456     DOI: 10.1179/1607845415Y.0000000033

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  14 in total

1.  Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.

Authors:  Pierre Decazes; Stéphanie Becker; Mathieu Nessim Toledano; Pierre Vera; Paul Desbordes; Fabrice Jardin; Hervé Tilly; Isabelle Gardin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-28       Impact factor: 9.236

2.  Predictive value of 18F-FDG PET/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial.

Authors:  Stéphanie Becker; Thomas Vermeulin; Anne-Ségolène Cottereau; Nicolas Boissel; Pierre Vera; Stéphane Lepretre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-21       Impact factor: 9.236

3.  PET-derived tumor metrics predict DLBCL response and progression-free survival.

Authors:  Prioty Islam; Jordan Goldstein; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2019-02-04

4.  Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study.

Authors:  Lale Kostakoglu; Federico Mattiello; Maurizio Martelli; Laurie H Sehn; David Belada; Chiara Ghiggi; Neil Chua; Eva González-Barca; Xiaonan Hong; Antonio Pinto; Yuankai Shi; Yoichi Tatsumi; Christopher Bolen; Andrea Knapp; Gila Sellam; Tina Nielsen; Deniz Sahin; Umberto Vitolo; Marek Trněný
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047

5.  Optimal PET-based radiomic signature construction based on the cross-combination method for predicting the survival of patients with diffuse large B-cell lymphoma.

Authors:  Chong Jiang; Ang Li; Yue Teng; Xiangjun Huang; Chongyang Ding; Jianxin Chen; Jingyan Xu; Zhengyang Zhou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-11       Impact factor: 10.057

6.  Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.

Authors:  Mathieu Nessim Toledano; P Desbordes; A Banjar; I Gardin; P Vera; P Ruminy; F Jardin; H Tilly; S Becker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-17       Impact factor: 9.236

7.  Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.

Authors:  Mingge Zhou; Yumei Chen; Honghui Huang; Xiang Zhou; Jianjun Liu; Gang Huang
Journal:  Oncotarget       Date:  2016-12-13

8.  Utility of baseline, interim and end-of-treatment 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase.

Authors:  Yu Chang; Xiaorui Fu; Zhenchang Sun; Xinli Xie; Ruihua Wang; Zhaoming Li; Xudong Zhang; Guangyao Sheng; Mingzhi Zhang
Journal:  Sci Rep       Date:  2017-01-24       Impact factor: 4.379

9.  Value of total lesion glycolysis and cell-of-origin subtypes for prognostic stratification of diffuse large B-cell lymphoma patients.

Authors:  Chong Jiang; Yue Teng; Zhong Zheng; Zhengyang Zhou; Jingyan Xu
Journal:  Quant Imaging Med Surg       Date:  2021-06

10.  Functional Parameters of 18F-FDG PET/CT in Patients with Primary Testicular Diffuse Large B-Cell Lymphoma.

Authors:  Jing Yang; Sha Zhu; Fuwen Pang; Miao Xu; Yiting Dong; Jianqi Hao; Xuelei Ma
Journal:  Contrast Media Mol Imaging       Date:  2018-09-27       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.